In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antegren: Shaking Up the MS Market?

Executive Summary

The dynamics of specialty chronic care markets suggest that Biogen Idec and Elan's highly anticipated Antegren may have trouble turning the scrappy $3.5 billion MS market on its head, at least right away.
Advertisement

Related Content

The New Oral MS Drugs: The Challenges in Dislodging Biologics
Drug Safety, the Sequel: This Time It's Specialist Products
Serono Deals Its Way Into Oncology
Schering: Addressing the Specialist Challenge
Is Switzerland Becoming Europe's Biotech Capital?
Deal Early, Less Often: ZymoGenetics' Broad Deal with Serono
Promoting Me-Too Biologicals: Portfolio vs. Single Product Approach
Biogen Defends its Specialist Market
The Serono/Pfizer Rebif Co-Promotion: Just Act One?
Serono's Global Ambitions

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel